From the Cochrane Library: Systemic Treatments for Metastatic Cutaneous Melanoma

摘要

Melanoma is the most lethal type of skin cancer, with only a 22.5% 5-year survival rate for stage IV (metastatic) disease[1]. Furthermore, with its steadily increasing incidence rate of 5-7% per year predicted through 2031, melanoma represents a significant health burden in the United States[1]. Treatment options for metastatic melanoma have changed dramatically with novel therapeutic strategies. However, a consensus on treatment and quality of evidence has yet to be established. “Systemic treatments for metastatic cutaneous melanoma,” a 2018 Cochrane review, assesses the beneficial and harmful effects of these new classes of drugs in treating unresectable metastaticmelanoma, defined as stage IIIC or stage IV[2].